IITRI NEWS
NEWS
We are ready to answer your questions and provide guidance.
News
Zika Poster Presentation at ASM Biothreats 2018 Meeting
IITRI will be presenting a poster at the ASM Biothreats 2018 Meeting, February 12-14 in Baltimore, MD. For more details, please contact us. Title: Humoral and cellular immune dynamics following Zika virus secondary challenge in non-human primates. Authors: J. M....
Dave McCormick Presenting at Eurotox 2017
Dave McCormick, IITRI's Director, will be presenting at Eurotox 2017 in a symposium session: Toxicology and Cellular Mechanisms of Electromagnetic Fields (EMF) – Health Aspects of Exposure to EMF Emitted by Wireless Mobile Systems and Emerging Technologies. His talk...
Expansion of ABSL-3 NHP Capacity at IITRI
IITRI now has expanded animal biosafety level 3 (ABSL-3) capacity to conduct pathogen challenge studies for vaccines or therapeutics in non-human primates (NHPs). Our ABSL-3 laboratories include head-only aerosol infection by inhalation exposure and plethysmography...
Zika Virus (ZIKV) Mouse Pregnancy Model Now Available
A mouse pregnancy model is now available from IITRI to evaluate the ability of vaccines or antivirals for protection against Zika virus (ZIKV) maternal-fetal viral transmission and resulting fetal defects such as microcephaly. Details of this mouse model and its use...
IITRI Announces New Flow Cytometry Services
IITRI is pleased to announce the addition of immunophenotyping services using flow cytometry to our ex vivo assay offerings. In flow cytometry, multiple properties can be analyzed simultaneously at the single cell level by generating a stream of cells in single-file...
IITRI Announces Expansion of Immunology Capabilities
IITRI is pleased to announce the expansion of our infectious disease immunology capabilities with the recent hiring of Justin Richner, PhD, to the position of Research Biologist, Viral Immunology. Dr. Richner’s research focus includes viral pathogenesis and host...
IITRI Chosen As Member of Nonclinical Studies Network
IITRI was one of 7 organizations chosen as a member of a Nonclinical Studies Network created by BARDA to aid in the successful development of medical countermeasures for biological threats. Nonclinical studies supporting treatments for biological threats is especially...
IITRI at IMED Meeting on Zika Mouse and Macaques Models
IITRI will be presenting at the upcoming International Meeting on Emerging Diseases and Surveillance (IMED) November 4-7, 2016 in Vienna, Austria, on Zika Mouse and Macque Models developed by our Molecular and Microbiology team. For more details, please contact us....
IITRI Awarded Over $4.7M BARDA Contracts
IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control...
NCI Awards IITRI $29.8 Million for 2 New Programs
The National Cancer Institute’s Division of Cancer Treatment and Diagnosis (DCTD) has awarded IITRI $29.8 million for two major 5-year new programs. The DCTD supports many programs that facilitate the development of cancer therapeutics from the bench to the patient,...
Recent Comments